Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025
Operating activities
Net income	$ 34,540	$ 93,511
Adjustments to reconcile net income to cash provided by operating activities:
Provision for bad debts	1,269	1,001
Deferred tax (benefit) expense	(1,832)	6,748
Depreciation and amortization	29,159	19,923
Amortization of developed technology and backlog	17,373	11,713
Amortization of debt discount and issuance costs	2,669	4,407
Gain on extinguishment of debts, net	0	(14,207)
Equity-based compensation	11,011	11,343
Change in fair value of contingent consideration	(10,438)	1,014
Provision for certain non-trade receivables	10,922	0
Warranty provision	9,076	10,290
Inventory reserve	5,204	3,360
Other non-cash	730	(2,017)
Changes in operating assets and liabilities	(13,207)	(88,941)
Net cash provided by operating activities	96,476	58,145
Investing activities
Purchase of property, plant and equipment	(20,844)	(14,496)
Acquisition, net of cash acquired	(160,869)	(164,916)
Investment in securities	(1,000)	0
Net cash used in investing activities	(182,713)	(179,412)
Financing activities
Proceeds from issuance of other debt	58,185	108,659
Proceeds from issuance of convertible notes	0	345,000
Premium paid on capped call	0	(35,087)
Fees paid on issuance of convertible notes	0	(10,434)
Repayments of other debt	(67,551)	(119,181)
Repayments of term loan facility	0	(233,875)
Repayments of convertible notes	0	(78,363)
Dividends paid on Series A Redeemable Perpetual Preferred Stock	(4,308)	0
Contingent consideration payments	(2,574)	(1,204)
Other financing	(2,040)	(1,033)
Net cash used in financing activities	(18,288)	(25,518)
Effect of exchange rate changes on cash and cash equivalent balances	1,821	5,747
Net change in cash and cash equivalents and restricted cash	(102,704)	(141,038)
Cash and cash equivalents, and restricted cash beginning of period	245,984	364,141
Cash and cash equivalents and restricted cash, end of period	$ 143,280	$ 223,103